Puma Biotechnology (PBYI) Stock Highlights

2.75 | -1.08%

2024-12-21 06:35:35

Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.

Statistics

Range Today

2.74 2.89

Volume Today 360.5K

Range 1 Year

2.23 7.73

Volume 1 Year 115.61M

Range 3 Year

1.6 7.73

Volume 3 Year 277.71M

Range 10 Year

1.6 252.92

Volume 10 Year 1.9B

Highlights

Market Capitalization 148.61M (small)

Floating Shares 31.91M

Current Price 2.75

Price To Earnings 18.83

Price To Book 2.57

Earnings Per Share 0.18

Payout Ratio 0%

Performance

Latest -1.08%

1 Month +0.36%

3 Months +8.7%

6 Months -11%

1 Year -30.56%

3 Years -21.65%

5 Years -68.28%

10 Years -98.75%

Benchmarks

Market Capitalization

200 / 368

Gross Profits

37 / 278

Total Revenue

53 / 300

Total Rank

39 / 368

Free Cashflow

46 / 352

Performance 5 years

195 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.